Compare FAMI & COCP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FAMI | COCP |
|---|---|---|
| Founded | 2015 | 2006 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.0M | 15.6M |
| IPO Year | 2017 | 2011 |
| Metric | FAMI | COCP |
|---|---|---|
| Price | $1.26 | $1.50 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 6.0K | ★ 4.3M |
| Earning Date | 08-04-2025 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 54.65 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $12,712,091.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.10 | $0.86 |
| 52 Week High | $2.22 | $2.19 |
| Indicator | FAMI | COCP |
|---|---|---|
| Relative Strength Index (RSI) | 50.38 | 62.26 |
| Support Level | $1.20 | $0.95 |
| Resistance Level | $1.39 | $1.99 |
| Average True Range (ATR) | 0.10 | 0.17 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 37.50 | 48.55 |
Farmmi Inc is an investment holding company. Through its subsidiaries, it acts as a supplier of agricultural products. It is an agricultural technology enterprise focused on its supply chain platform by promoting edible mushroom products and agriculture technology. Its product offerings include tapioca, corn, red dates, shiitake mushrooms, mu er fungus, other edible fungi, and other agricultural products. Geographically, the company's products are sold in China, Southeast Asia, Japan, North America, Europe and the Middle East under the Forasen and Farmmi brands.
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).